Table 1.

Approved vaccines that have received the attention of the scientific community concerning coronavirus disease 2019 as potential prototypes for developing mucosal coronavirus disease 2019 vaccines

Name of vaccine	Form	Immunity	Dosage	Route
OPV (oral poliovirus vaccine)	Live attenuated poliovirus (Sabin strain types 1, 2 or 3)	Poliovirus-specific mucosal immunity	2 doses	Oral
BCG (Bacille Calmette-Guerin)	Live attenuated bacteria Mycobacterium bovis	Mycobacterium-specific mucosal and systemic immunity	0.05 mL until 1 yr of age; 0.1 mL thereafter	Intradermal injection subcutaneous
MMR (measles, mumps and rubella vaccines)	Weakened forms of the measles, mumps and rubella viruses	Measles, mumps and rubella-specific systemic and mucosal immunity	2 doses	Subcutaneous injection
RV1 (Rotarix®)	Live-attenuated rotavirus	Rotavirus-specific mucosal immunity	2 doses	Oral
RV5 (RotaTeq®)	Live-attenuated rotavirus	Rotavirus-specific mucosal immunity	3 doses	Oral